Study Examining Glofitamab With GemOX in Patients With R/R DLBCL Meets Primary Endpoint

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

Related Keywords

Sweden ,Swedish ,Mabthera Rituxin ,Levi Garraway ,Krish Patel ,Lymphoma Program ,Swedish Cancer Institute In Seattle ,Global Product Development At Roche ,Genentech ,Evaluating Glofitamab ,Combination With Gemcitabine ,Participants With ,Refractory Diffuse Largeb Cell ,Swedish Cancer Institute ,Global Product Development ,